Karyopharm Therapeutics
Sohanya Cheng joined Karyopharm in June 2021 and is responsible for leading the company’s Sales and Commercial Operations functions.
Sohanya brings 17 years of biopharmaceutical commercialization and research experience to Karyopharm, predominately in the oncology space. Prior to joining Karyopharm, Sohanya served as Vice President, Head of Marketing and Corporate Affairs at Arrowhead Pharmaceuticals and prior to this role, spent over 10 years within the commercial organization at Amgen. While at Amgen, Sohanya held a variety of sales and marketing leadership roles supporting the commercialization of key oncology brands, including Kyprolis® for multiple myeloma and Blincyto® for acute lymphoblastic lymphoma, and served as Amgen’s Executive Director, Head of Marketing & Sales for their multiple myeloma business.
Sohanya holds an MBA from the MIT Sloan School of Management and a BSc and MA from the University of Cambridge, UK.
This person is not in any offices
Karyopharm Therapeutics
13 followers
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an innovation-driven pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1).